Respiratory Syncytial Virus Infection (RSV) Treatment Market: Introduction
- Respiratory syncytial virus (RSV) is a common and transmissible virus causing infection of the respiratory tract in children and adults. This infection can lead to respiratory infections such as bronchiolitis and pneumonia. Symptoms of respiratory syncytial virus infection are mostly visible about 4 to 6 days post virus exposure. It includes congested or runny nose, dry cough, fever, sore throat, sneezing, and headache. Presently, no specific approved drugs or vaccines are available for the treatment or prevention of RSV infection.
Key Drivers, Restraints, and Opportunities of Global Respiratory Syncytial Virus Infection (RSV) Treatment Market
- High incidence rate of RSV infection among infants and rising interest of different biotechnology companies to develop various recombinant drugs for RSV infection treatment are expected to drive the RSV treatment market
- Respiratory syncytial virus (RSV) is the main cause of bronchiolitis among infants. According to CDC, it was reported that RSV leads to approximately 58,000 hospitalizations among children younger than 5 years old in the U.S. each year. As per WHO statistics, respiratory syncytial virus (RSV) affects 64 million infections and causes 160,000 deaths annually. A surge in the patient pool infected with RSV is anticipated to boost the respiratory syncytial virus infection (RSV) treatment market.
- Several unmet needs in the global respiratory syncytial virus (RSV) treatment market are creating significant opportunities for existing players and new entrants in the global market. The key players are collaboratively focusing on launching a cost-effective and efficacious biologic in order to treat RSV diseases. Moreover, the lack of appropriate in-vitro facilities for conducting research studies for the development of new treatment alternatives is likely to hinder the market.
- The COVID 19 virus spread to almost all countries worldwide. There was an imposition of a travel ban and shutdown of manufacturing units, offices & marketplaces by governments in order to curb the spread of the virus. The impact of COVID 19 has been unprecedented and staggering the respiratory syncytial virus infection (RSV) treatment market in 2020. The pandemic has revealed some harsh truth about the limitations of healthcare resources available for combating this novel virus for which no vaccine and no treatment exist.
North America to Capture Major Share of Global Respiratory Syncytial Virus Infection (RSV) Treatment Market
- North America is expected to account for a major share of the global respiratory syncytial virus infection (RSV) treatment market owing to the growing prevalence of RSV infection among infants and a surge in awareness about the effect of RSV infection
- The respiratory syncytial virus infection (RSV) treatment market in Asia Pacific is expected to expand at a rapid pace during the forecast period due to the development of healthcare systems and surge in numbers of government initiatives in the region
Key Players Operating in Global Respiratory Syncytial Virus Infection (RSV) Treatment Market
The key market players have been focusing on increasing R&D activities and launching new products for specific applications. Major players operating in the global respiratory syncytial virus infection (RSV) treatment market are listed below:
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- ReViral Ltd.
- Bausch Health
- AbbVie Inc.
Global Respiratory Syncytial Virus Infection (RSV) Treatment Market: Research Scope
Global Respiratory Syncytial Virus Infection (RSV) Treatment Market, by Route of Administration
Global Respiratory Syncytial Virus Infection (RSV) Treatment Market, by Treatment Type
- Supportive Care
- Hospital Care
Global Respiratory Syncytial Virus Infection (RSV) Treatment Market, by Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
